Equity Components [Axis]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Business Combination [Axis]
Enviro Threapeutics Inc [Member]
Sale of Stock [Axis]
Equity Line of Credit [Member]
Antidilutive Securities [Axis]
Warrants to Purchase Common Stock [Member]
Restricted Stock Units (RSUs) [Member]
Legal Entity [Axis]
Prevail Infoworks Inc [Member]
Cross Current Capital LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Master Service And Technology Agreement [Member]
Consulting Agreement [Member]
Helena Global Investment Opportunities I LTD [Member]
ATM Agreement [Member]
Security Purchase Agreement [Member]
Pre-Funded Warrant [Member]
Warrant [Member]
Pre-Funded Warrant [Member]
Common Warrants [Member]
Plan Name [Axis]
2023 Equity Incentive Plan [Member]
Award Type [Axis]
Statistical Measurement [Axis]
Minimum [Member]
Maximum [Member]
Exercise Price Range [Axis]
Exercise Price Range One [Member]
Warrant One [Member]
Exercise Price Range Two [Member]
Warrant Two [Member]
Exercise Price Range Three [Member]
Warrant Three [Member]
Exclusive License Agreement [Member]
Product and Service [Axis]
Phase I Clinical Trial [Member]
Item 1 And 2 [Member]
Phase II [Member]
Item 3 [Member]
Phase II Clinical Trial [Member]
Geographical [Axis]
Non-US [Member]
Food and Drug Administration [Member]
Item 1, 2 and 3 [Member]
Item 4 [Member]
Phase III Clinical Trial [Member]
Enviro Cedars License Agreements [Member]
Phase III [Member]
Lonza Amendment [Member]
Consolidation Items [Axis]
Operating Segments [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Pharmaceutical Development Services Agreement [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Statement of Financial Position [Abstract]
ASSETS
Current Assets
Cash and cash equivalents
Vendor advances, net
Prepaid expenses and other current assets
Total Current Assets
Deferred offering costs
Intangible assets, net
Total Other Assets
TOTAL ASSETS
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities
Accounts payable and accrued expenses
Total Current Liabilities
Commitments and contingencies
Shareholders’ Equity
Preferred stock, par value $0.001, 20,000,000 shares authorized; no shares issued and outstanding, respectively;
Common stock, par value $0.001, 100,000,000 shares authorized; 21,411,198 and 20,821,353 shares issued and outstanding, respectively;
Additional paid-in capital
Accumulated deficit
Total Shareholders’ Equity
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Revenues
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income:
Interest income
Total other income
NET LOSS
BASIC LOSS PER COMMON SHARE
DILUTED LOSS PER COMMON SHARE
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING DILUTED
Statement [Table]
Statement [Line Items]
Balance
Balance, shares
Issuance of common shares sold through the At the Market (ATM) offering, net of offering costs
Issuance of common shares sold through the At the Market (ATM) offering, net of offering costs, shares
Fair value of vested restricted stock units
Net loss
Proceeds from the sale of pre-funded warrants, net of offering costs
Issuance of common shares upon the exercise of pre-funded warrants
Issuance of common shares upon the exercise of pre-funded warrants, shares
Fair value of common shares to be issued for vendor advance and deferred offering costs
Fair value of common shares to be issued for vendor advance and deferred offering costs, shares
Fair value of vested restricted stock units, shares
Balance
Balance, shares
Statement of Cash Flows [Abstract]
Cash Flows from Operating Activities
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of intangible asset
Amortization of vendor advances
Fair value of vested restricted stock units
Changes in operating assets and liabilities:
Vendor advances
Prepaid expenses and other current assets
Accounts payable and accrued expenses
Net cash used in operating activities
Proceeds from the At the Market (ATM) offering
Proceeds from the sale and exercise of prefunded warrants
Payment of deferred offering costs
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Supplemental cash flows disclosures:
Interest paid
Taxes paid
Supplemental non-cash financing disclosures:
Common shares issued for deferred offering costs
Common shares issued for vendor advances
Reclassification of deferred offering costs to shareholders’ equity
Accrual of deferred offering costs
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Accounting Policies [Abstract]
BASIS OF PRESENTATION
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Vendor Agreements
VENDOR AGREEMENTS
Deferred Offering Costs
DEFERRED OFFERING COSTS
Equity [Abstract]
SHAREHOLDERS’ EQUITY
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES
Segment Reporting [Abstract]
SEGMENT INFORMATION
Subsequent Events [Abstract]
SUBSEQUENT EVENTS
Basis of Consolidation
Use of Estimates
Concentration of Credit Risk
Cash Equivalents
Intangible Assets
Impairment of Long-Lived Assets
Income (Loss) Per Share
Deferred Offering Costs
Fair Value Measurements
Recent Accounting Pronouncements
SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES
SCHEDULE OF VENDOR ADVANCES
SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY
SCHEDULE OF WARRANT ACTIVITY
SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS
SCHEDULE OF SEGMENT EXPENSES
Net loss
Cash in operations
Cash and short-term investments
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total
Restructuring Cost [Table]
Restructuring Cost and Reserve [Line Items]
Money market funds
Intangible assets useful life
Acquisition cost
Amortization expenses
Intangible assets unamortized balance
Impairment of intangible assets
Deferred offering additional cost
Deferred offering costs
Amortized cost
Amortized cost, net
DisclosureOfVendorAdvancesTable [Table]
Vendor advances, gross
Less: accumulated amortization
Vendor advances, net
VendorAdvancesDisclosureTable [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments for advance to affiliate
Monthly payment
Unamortizaed balance
Number of shares issued, value
Numbr of RSU issued
Vendor payment advance
Vendor advances amount
Vendor advances
Amortization expense relating to vendor advances
DeferredOfferingCostsDisclosureTable [Table]
Number of common stock issued
Number of shares issued
Stock issued value
Sale of stock value
Deferred charges
Amortized cost
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Restricted Shares, Unvested Beginning balance
Fair Value, Unvested, Beginning balance
Weighted Average Grant Date Fair Value, Beginning balance
Number of Restricted shares Granted
Fair Value, Granted
Weighted Average Grant Date Fair Value, Granted
Number of Restricted shares Vested
Fair Value, Vested
Weighted Average Grant Date Fair Value, Vested
Number of Restricted shares Forfeited
Fair Value, Forfeited
Weighted Average Grant Date Fair Value, Forfeited
Number of Restricted Shares, Unvested Ending balance
Fair Value, Unvested, Ending balance
Weighted Average Grant Date Fair Value, Ending balance
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Shares, Beginning Balance
Exercise Price Range Per Share, Beginning
Weighted Average Exercise Price Warrant Warrant, Beginning Balance
Warrants Shares, Granted
Exercise Price Range Per Share, Granted
Weighted Average Exercise Price Warrant, Granted
Warrants Shares, Cancelled
Exercise Price Range Per Share, Cancelled
Weighted Average Exercise Price Warrant, Cancelled
Warrants Shares, Exercised
Exercise Price Range Per Share, Exercised
Weighted Average Exercise Price Warrant, Exercised
Warrants Shares, Forfeited/Expired
Exercise Price Range Per Share, Forfeited/Expired
Weighted Average Exercise Price Warrant, Forfeited/Expired
Warrants Shares, Ending Balance
Exercise Price Range Per Share, Ending
Weighted Average Exercise Price Warrant, Ending Balance
Number of Shares Warrants, Vested and exercisable
Exercise Price Range Per Share, Vested and exercisable
Weighted Average Exercise Price, Vested and exercisable
Range of exercise prices
Warrants Outstanding, Number Outstanding
Warrants Outstanding, Average Remaining Contractual Life (in years)
Warrants Outstanding, Weighted Average Exercise Price
Warrants Exercisable, Number Exercisable
Warrants Exercisable, Average Remaining Contractual Life (in years)
Warrants Exercisable, Weighted Average Exercise Price
Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]
Subsidiary, Sale of Stock [Line Items]
Purchase price of pre-funded unit
Sale of stock rate
Sale of stock
Sale of stock, number of shares issued in transaction
Net proceeds after the deduction of offering costs
Exercisable price per share
Warrants to purchase of common stock
Shares issued, price per share
Net proceeds received from financing
Exercise price
Warrants exercised
Warrants unexercised
Common stock reserved for future issuance
Shares available for grant
Stock compensation-related expense
Unamortized compensation
Intrinsic value for warrant shares
Product Liability Contingency [Table]
Product Liability Contingency [Line Items]
License fee
Patent protection costs
Annual maintenance fee
Royalty percentage
Other non-royalty sublicense fees percentage
Payment for milestone
Net sales
Minimum requirerment of capital
Patent product sales
License agreement description
Payments for purchase of assets
Milestone payments payable
Segment Reporting [Table]
Segment Reporting [Line Items]
Revenue
Research and development, less officer compensation
Officer compensation and wages
Insurance
Stock-based compensation
Operating expenses
Other income (expenses)
NET LOSS
Number of reportable segments
Subsequent Event [Table]
Subsequent Event [Line Items]
Total committed amount
Vendor advances net.
Stock issued during period value sale of common shares and prefunded warrants net of offering costs.
Amortization of vendor advances.
Increase decrease in vendor advances.
Proceeds from at market offering
Issuance of common shares for deferred offering costs.
Issuance of common shares for vendor advances.
Reclassification of deferred offering costs to shareholders equity.
Accrual of deferred offering costs
Enviro Threapeutics Inc [Member]
Deferred offering additional costs.
Equity Line of Credit [Member]
Disclosure of Vendor Agreements [Text Block]
Vendor advances current.
Amortization expense vendor advances.
Schedule of Vendor Advances [Table Text Block]
Vendor advances gross.
Vendor advances accumulated amortization.
Master Service And Technology Agreement [Member]
Monthly payment.
Consulting Agreement [Member]
Vendor payment advances.
Deferred Offering Costs Disclosure [Text Block]
Helena Global Investment Opportunities I LTD [Member]
ATM Agreement [Member]
Security Purchase Agreement [Member]
Pre-Funded Warrant [Member]
Pre-Funded Warrant [Member]
Common Warrants [Member]
Stock issued during period shares issuance of common shares upon exercise of prefunded warrants.
Warrants unexercised.
2023 Equity Incentive Plan [Member]
Fair value of options granted.
Fair value of options forfeited.
Fair value of restricted stock units.
Fair value of unamortized compensation.
The number of shares reserved for issuance pertaining to the outstanding stock warrants as of the balance sheet date for all warrants in the customized range of exercise prices.
Share based compensation shares exercisabler other than stock option plans exercise price range granted.
The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period.
Share based compensation shares exercisabler other than stock option plans exercise price range cancelled.
The weighted average fair value at grant date for nonvested equity-based awards cancelled during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
The number of equity-based payment instruments, excluding stock (or unit) options, that were exercised during the reporting period.
Share based compensation shares exercisabler other than stock option plans exercise price range exercised.
The weighted average fair value at grant date for nonvested equity-based awards exercised during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
Share based compensation shares exercisabler other than stock option plans exercise price range forfeited.
Share based compensation arrangement by share based payment award other than options vested and excercisable in period.
The number of shares reserved for issuance pertaining to the warrants vested and exercisable as of the balance sheet date for all warrants in the customized range of exercise prices.
Schedule of Warrants Outstanding and Exercisable [Table Text Block]
Exercise Price Range One [Member]
Warrant One [Member]
Exercise Price Range Two [Member]
Warrant Two [Member]
Exercise Price Range Three [Member]
Warrant Three [Member]
Number of shares warrants exercisable.
Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average remaining contractual terms.
Share based compensation arrangements by share based payment award equity instruments other than options nonvested weighted average exercise price.
License fee.
Exclusive License Agreement [Member]
Royalty percentage.
Other nonroyalty sublicense fees percentage.
Payment for milestones.
Phase One Clinical Trial [Member]
Item One And Two [Member]
Phase Two [Member]
Item Three [Member]
Phase Two Clinical Trial [Member]
Patent protection costs.
Food and Drug Administration [Member]
Item 1, 2 and 3 [Member]
Item Four [Member]
Minimum requirerment of capital.
Patent product sales percentage.
Phase Three [Member]
Enviro Cedars License Agreements [Member]
Phase Three Clinical Trial [Member]
License agreement description.
Lonza Amendment [Member]
Fair value of vested restricted stock units.
Stock issued during period value fair value of common shares issued for vendor advance and deferred offering costs.
Stock issued during period shares fair value of common shares issued for vendor advance and deferred offering costs.
Stock issued during period value issuance of common shares upon exercise of prefunded warrants.
Stock issued during period value issuance of common shares sold through at market ATM offering net of offering costs
Stock issued during period shares issuance of common shares sold through at market ATM offering net of offering costs
Deferred charges.
Warrants to Purchase Common Stock [Member]
Prevail Infoworks Inc [Member]
Cross Current Capital LLC [Member]
Pharmaceutical Development Services Agreement [Member]
Pre-Funded Warrant [Member] [Default Label]
Assets, Current
Assets, Noncurrent
Assets
Liabilities, Current
Equity, Attributable to Parent
Liabilities and Equity
Operating Income (Loss)
Nonoperating Income (Expense)
Shares, Outstanding
FairValueOfVestedRestrictedStockUnits
IncreaseDecreaseInVendorAdvances
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Payments of Financing Costs
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
Deferred Charges, Policy [Policy Text Block]
Deferred Offering Costs [Default Label]
Vendor advances accumulated amortization
Amortization of Deferred Charges
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable